EUVIMEDEUVIMED entdecken
Crossref

Prognostic Significance of Preoperative Serum CA19-9-to-CEA Ratio in Stage I-III Colorectal Cancer Post-Resection

Takashi Aida iD, Teppei Kamada, Junji Takahashi, Daisuke Yamagishi, Eisaku Ito, Norihiko Suzuki, Taigo Hata, Masashi Yoshida, Hironori Ohdaira, Yutaka Suzuki

The American Surgeon™ · 2026

DOI: 10.1177/00031348251356745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, 2026. Verfasst von Takashi Aida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, International University of Health and Welfare Hospital, Nasushiobara-shi, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colectomy, Carcinoembryonic Antigen, CA-19-9 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

During colorectal cancer (CRC) surveillance, tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), play important roles in the diagnosis, prediction, and monitoring of tumors. Herein, we devised a novel combined index comprising the CA19-9-to-CEA ratio and investigated its prognostic value in patients with stage I-III CRC after resection.

Methods

This retrospective study included 306 patients who underwent radical resection between 2011 and 2020. CA19-9 and CEA levels were evaluated preoperatively. The CA19-9-to-CEA ratio cutoff value was determined via receiver-operating characteristic analysis using the survival status at the 5-year follow-up evaluation. Multivariate Cox proportional hazard models were used to assess disease-free survival (DFS) and overall survival (OS).

Results

According to the multivariate analysis, T3 or T4 tumor ( P = 0.041; hazard ratio [HR], 2.54), pathological stage III ( P = 0.001; HR, 3.07), serum CEA level ≥5.0 ng/mL ( P = 0.018; HR, 2.11), and high CA19-9-to-CEA ratio ( P = 0.015; HR, 2.89) were independently associated with DFS. Age 65≥ years ( P = 0.03; HR, 2.86), pathological stage III ( P = 0.001; HR, 2.00), high neutrophil-to-lymphocyte ratio ( P = 0.003; HR, 2.27), and high CA19-9-to-CEA ratio ( P = 0.009; HR, 3.16) were independent prognostic factors for OS. Patients with high CA19-9-to-CEA ratios had significantly worse DFS ( P < 0.001) and OS ( P < 0.001).

Discussion

A high CA19-9-to-CEA ratio can be used for detailed risk prediction in patients with CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColectomyCarcinoembryonic AntigenCA-19-9 AntigenBiomarkers, TumorPrognosisPredictive Value of TestsRetrospective StudiesReference ValuesProportional Hazards ModelsROC CurveNeoplasm StagingLeukocyte CountNeutrophilsLymphocytesSurvival RateDisease-Free SurvivalPreoperative PeriodHumansMaleFemaleAgedMiddle Aged

Stichwörter der Autor:innen

colorectalgastrointestinalsurgical oncology

Substanzen

Carcinoembryonic AntigenCA-19-9 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, International University of Health and Welfare Hospital, Nasushiobara-shi, Japan.

ORCID-Profile: Takashi Aida

Zitieren

APA

Aida, T., Kamada, T., Takahashi, J., Yamagishi, D., Ito, E., Suzuki, N., Hata, T., Yoshida, M., Ohdaira, H., & Suzuki, Y. (2026). Prognostic Significance of Preoperative Serum CA19-9-to-CEA Ratio in Stage I-III Colorectal Cancer Post-Resection. The American Surgeon™. https://doi.org/10.1177/00031348251356745

Vancouver

Aida T, Kamada T, Takahashi J, Yamagishi D, Ito E, Suzuki N, et al. Prognostic Significance of Preoperative Serum CA19-9-to-CEA Ratio in Stage I-III Colorectal Cancer Post-Resection. The American Surgeon™. 2026. doi:10.1177/00031348251356745

BibTeX
@article{Aida2026,
  author = {Aida, Takashi and Kamada, Teppei and Takahashi, Junji and Yamagishi, Daisuke and Ito, Eisaku and Suzuki, Norihiko and Hata, Taigo and Yoshida, Masashi and Ohdaira, Hironori and Suzuki, Yutaka},
  title = {Prognostic Significance of Preoperative Serum CA19-9-to-CEA Ratio in Stage I-III Colorectal Cancer Post-Resection},
  journal = {The American Surgeon™},
  year = {2026},
  doi = {10.1177/00031348251356745}
}
Kostenlos starten →